Drug Profile
RGLS 4326
Alternative Names: RGLS-4326Latest Information Update: 14 Dec 2021
Price :
$50
*
At a glance
- Originator Regulus Therapeutics
- Class Antisense oligonucleotides; MicroRNAs
- Mechanism of Action MIRN17 microRNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autosomal dominant polycystic kidney disease
Most Recent Events
- 12 Nov 2021 Regulus Therapeutics completes a phase I trial in Autosomal dominant polycystic kidney disease (In adults, In the elderly) in USA (SC) (NCT04536688)
- 13 Oct 2021 Discontinued - Phase-I for Autosomal dominant polycystic kidney disease (In the elderly, In adults) in USA (SC)
- 10 Aug 2021 Regulus plans to discuss its approach for the remaining partial clinical hold requirements with US FDA for IND in Autosomal dominant polycystic kidney disease in the third quarter of 2021